INTERSTITIAL LUNG DISEASE · DIFFUSE PARENCHYMAL LUNG DISEASE · ILD
A physician-led, laboratory-verified treatment programme designed to reduce pulmonary inflammation, slow fibrotic progression and improve respiratory function — tailored to the individual biology, disease subtype and clinical profile of each ILD patient.
Request Medical ConsultationAbout the Condition
Interstitial Lung Disease (ILD) is a broad group of disorders characterised by progressive scarring (fibrosis) and inflammation of the lung interstitium — the tissue surrounding the alveoli. As fibrosis advances, the lung becomes stiff, gas exchange deteriorates, and patients experience progressive breathlessness, reduced exercise tolerance and declining oxygen saturation.
ILD encompasses over 200 distinct conditions. Some are triggered by autoimmune processes, occupational exposures, drug toxicity or radiation. Others — such as idiopathic pulmonary fibrosis — have no identifiable cause. Regardless of aetiology, the common pathway involves chronic inflammation, fibroblast activation and irreversible structural remodelling of the lung parenchyma.
Standard pharmacological management typically involves antifibrotic agents (pirfenidone, nintedanib) and immunosuppressants, which may slow progression but do not reverse existing fibrosis. Lung transplantation remains the only definitive option for end-stage disease — which is precisely where our programme offers a meaningful additional dimension.
Sarcoidosis-related ILD
Granulomatous inflammation affecting the lung parenchyma, often with bilateral hilar lymphadenopathy. May be self-limiting or progress to chronic pulmonary fibrosis. Requires careful immunological assessment before cellular therapy.
Drug-induced ILD
Lung injury caused by medications including methotrexate, amiodarone, bleomycin and certain biologics. Presentation ranges from acute pneumonitis to chronic fibrosis. Offending agent withdrawal is essential before treatment.
Radiation-induced ILD
Pulmonary fibrosis developing weeks to months after thoracic radiation therapy. Severity depends on radiation dose, field size and concurrent chemotherapy. Typically affects the irradiated lung zone but may extend beyond.
Occupational ILD (asbestosis, silicosis)
Chronic fibrotic lung disease resulting from prolonged inhalation of mineral dusts. Asbestosis follows asbestos exposure; silicosis follows crystalline silica. Both produce progressive, irreversible fibrosis with characteristic radiological patterns.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, disease subtype, pulmonary function parameters, imaging findings and overall clinical profile.
We do not offer a cure for ILD. Our programme is designed to target the biological mechanisms driving fibrotic progression — with the clinical objective of stabilising lung function, reducing inflammatory burden, and improving respiratory quality of life.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2017 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
22
ILD patients treated
70%
demonstrated measurable stabilisation of FVC within 3–6 months
59%
showed improvement in DLCO from baseline
64%
reported reduced dyspnoea severity during daily activities
−0.8 pts
average GAP Index change over the first 12 months
68%
maintained functional stability at follow-up beyond 18 months
Improved six-minute walk distance
55%
Reduced supplemental oxygen requirement at rest
41%
Increased exercise tolerance during rehabilitation
59%
Reduction in cough frequency and severity
50%
Improved sleep quality due to reduced nocturnal desaturation
46%
3–8 weeks
Initial functional response
3–6 months
Clinically meaningful change
1–2 years under continued monitoring
Functional stabilisation phase
Important: Outcomes depend on ILD subtype, baseline FVC and DLCO values, extent of fibrosis on HRCT, disease duration and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Two years on medication and my lung function kept dropping. After treatment in Warsaw, my pulmonologist measured stable values at three months and again at nine. He cut my steroid dose in half. I still get winded on stairs, but the decline stopped, and that was exactly what we were trying to achieve.”
Patient
Sarcoidosis-related ILD · Germany
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our ILD programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's pulmonary function, imaging, disease subtype and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion — not surgical instruments. No thoracic procedures, no lung biopsy required for treatment.
No general anaesthesia
Particularly important in ILD, where compromised respiratory reserve may make general anaesthesia high-risk.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the underlying biology, not just symptoms
Rather than managing symptoms alone, our protocol targets interstitial inflammation, fibroblast activation and immune dysregulation — the biological drivers of fibrotic progression.
Complements existing medication
Our programme is compatible with pirfenidone, nintedanib and immunosuppressive regimens. Patients do not need to discontinue existing treatment before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world. For patients with advanced ILD where long-haul travel may worsen hypoxaemia, this removes a major barrier to accessing care.
What It Is
MSCs are multipotent regenerative cells with documented immunomodulatory and antifibrotic properties. They are among the most extensively studied cell types in regenerative medicine and have demonstrated safety across thousands of clinical applications worldwide.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Interstitial Lung Disease
In ILD, chronic inflammation triggers fibroblast proliferation and excessive collagen deposition, progressively stiffening the lung and impairing gas exchange. MSCs address this mechanism by suppressing the inflammatory cascade, inhibiting myofibroblast differentiation, and creating conditions that favour tissue repair over further scarring.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, ILD subtype, pulmonary function data, imaging findings and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current pulmonary function data, HRCT findings, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation including spirometry, DLCO, HRCT imaging and laboratory results. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured respiratory rehabilitation sessions with our specialist, adapted to your current pulmonary function and exercise capacity. Available at our clinic or remotely coordinated with your local pulmonary team.
Your dedicated coordinator monitors pulmonary function, oxygen saturation trends and overall well-being. A medical-grade wearable bracelet supports continuous physiological data collection regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of ILD patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including acute respiratory exacerbation — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
FVC below 30% predicted with resting hypoxaemia refractory to supplemental oxygen
Post-Treatment
Dedicated pulmonary rehabilitation specialist
monitors respiratory function, oxygen saturation and exercise tolerance
Personalised respiratory rehabilitation programme
adapted to current pulmonary capacity and disease stage
Medical-grade wearable monitoring
continuous SpO₂, heart rate and activity data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in respiratory status
Continued clinical access
our medical team remains available for ongoing reassessment, repeat spirometry review and protocol adjustment
Pulmonary fibrosis develops over months and years. The biological response to cellular therapy follows a comparable trajectory. Post-treatment monitoring — including serial spirometry, DLCO measurement and HRCT comparison — is integral to evaluating treatment effect and guiding any subsequent intervention.
Get Started
If you or someone you love has been diagnosed with interstitial lung disease, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current pulmonary function and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
